Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
Biomarker and diagnostic research for alopecia universalis has been reported in the published literature.
5 clinical trials registered, 3 recruiting. Interventions under study include drug therapy and other interventions. Pipeline includes 2 PHASE4, 1 PHASE2. Research is primarily sponsored by academic and government institutions.
NCT ID | Title | Phase | Sponsor | Status |
|---|---|---|---|---|
[NCT07406204](https://clinicaltrials.gov/study/NCT07406204) |
Data assembled from 3 of 12 sources · Last updated Sep 17, 2026, 9:40 PM UTC
Tofacitinib vs Methotrexate for Severe Alopecia Areata (TOFA-MTX-AA)
PHASE4 |
Hayat Abad Medical Complex, Peshawar |
NOT_YET_RECRUITING |
[NCT06747611](https://clinicaltrials.gov/study/NCT06747611) | Evaluation of Microbiota Transplant Therapy in Patients With Alopecia Areata | PHASE2 | University of Minnesota | RECRUITING |
[NCT00069589](https://clinicaltrials.gov/study/NCT00069589) | Alopecia Areata Registry | — | M.D. Anderson Cancer Center | ACTIVE_NOT_RECRUITING |
[NCT06283316](https://clinicaltrials.gov/study/NCT06283316) | Systemic Treatments for Alopecia Areata Registry | — | Erasmus Medical Center | RECRUITING |
[NCT07381556](https://clinicaltrials.gov/study/NCT07381556) | Cyclosporine Or Methotrexate for Pediatric Alopecia Areata: Routine Clinical Care Effectiveness Study | PHASE4 | Erasmus Medical Center | RECRUITING |
90 publications have been identified in PubMed for alopecia universalis. Research spans Case Report / Case Series (36%), Clinical Trial Publication (27%), and Review / Meta-Analysis (13%).
Research Type | Count | % of Total |
|---|---|---|
Patient case studies | 32 | 36% |
Clinical study results | 24 | 27% |
Research summaries | 12 | 13% |
Disease patterns and progression | 10 | 11% |
Laboratory research | 5 | 6% |
Other research | 3 | 3% |
New treatment approaches | 3 | 3% |
Testing and diagnosis research | 1 | 1% |
Ajmani A (2026). [PMID: 42005506](https://pubmed.ncbi.nlm.nih.gov/42005506/). *JAAD Case Rep*. [Case Report / Case Series]
Migliorelli A (2026). [PMID: 42157622](https://pubmed.ncbi.nlm.nih.gov/42157622/). *Dermatitis*. [Other]
Vañó-Galván S (2026). [PMID: 41344610](https://pubmed.ncbi.nlm.nih.gov/41344610/). *Actas dermo-sifiliograficas*. [Clinical Trial Publication]
Fan A (2026). [PMID: 41656280](https://pubmed.ncbi.nlm.nih.gov/41656280/). *Stem cell research & therapy*. [Case Report / Case Series]
Pohoreski KT (2026). [PMID: 42110117](https://pubmed.ncbi.nlm.nih.gov/42110117/). *JPGN Rep*. [Case Report / Case Series]
Trost SU (2026). [PMID: 42039112](https://pubmed.ncbi.nlm.nih.gov/42039112/). *JCEM Case Rep*. [Case Report / Case Series]
Piraccini BM (2026). [PMID: 40985491](https://pubmed.ncbi.nlm.nih.gov/40985491/). *Journal of the European Academy of Dermatology and Venereology : JEADV*. [Clinical Trial Publication]
Li F (2026). [PMID: 41730433](https://pubmed.ncbi.nlm.nih.gov/41730433/). *Journal of the American Academy of Dermatology*. [Gene Therapy / Novel Therapeutics]
Gowda SK (2026). [PMID: 41108789](https://pubmed.ncbi.nlm.nih.gov/41108789/). *The International journal of risk & safety in medicine*. [Epidemiology / Natural History]
Alzahrani D (2026). [PMID: 41869422](https://pubmed.ncbi.nlm.nih.gov/41869422/). *Clin Cosmet Investig Dermatol*. [Case Report / Case Series]
AI-curated news mentioning alopecia universalis
Updated Mar 16, 2026
A case report highlights the development of vitiligo and alopecia universalis in a patient with myasthenia gravis after receiving rituximab therapy. This finding may prompt further investigation into the side effects of rituximab in rare disease populations.